What is an example of an MAO-B inhibitor given to newly diagnosed Parkinson's patients?

In the context of Parkinson's disease treatment, Selegiline is an example of a monoamine oxidase type B (MAO-B) inhibitor that is often used for newly diagnosed patients. MAO-B inhibitors work by preventing the breakdown of dopamine in the brain, which can help alleviate the motor symptoms associated with Parkinson's disease.

Selegiline specifically inhibits the enzyme monoamine oxidase B, which is more selective for the breakdown of dopamine compared to MAO-A. This selectivity is beneficial as it helps to enhance dopaminergic activity without significantly affecting other neurotransmitters that might be metabolized by MAO-A. By increasing dopamine levels, Selegiline can help improve motor function and may delay the need for more potent treatments like levodopa in early-stage Parkinson's.

Rasagiline is another MAO-B inhibitor and is also used in the treatment of Parkinson's disease, but in this case, Selegiline was chosen as the best-known early treatment option. Entacapone is a COMT inhibitor rather than an MAO-B inhibitor, while Amantadine is primarily an antiviral that is also used for Parkinson's symptoms but works through a different mechanism.